

AMENDMENT AFTER FINAL
U.S. Appln. No. 09/889,846

IN THE CLAIMS:

Please enter the following cancellations, amendments and/or additions.

Claims 1-16. (Cancelled).

Claim 17. (Previously presented) A method for normalization of C4+CD29+CD45RA+ lymphocyte populations comprising administering, to a subject afflicted with a disease wherein said populations are increased, a pharmaceutically effective amount of a composition comprising a water-soluble fraction from rhizomes of *Polypodium* and a lipid-soluble fraction from rhizomes of *Polypodium*; and a pharmaceutically acceptable carrier.

Claim 18. (Previously presented) The method of Claim 17, wherein said composition comprises 118 mg of said water-soluble fraction and 2 mg of said lipid-soluble fraction.

Claim 19. (Previously presented) A method for treatment of multiple sclerosis comprising administering, to a subject afflicted with multiple sclerosis, a pharmaceutically effective amount of a composition comprising a water-soluble fraction from rhizomes of *Polypodium* and a lipid-soluble fraction from rhizomes of *Polypodium*; and a pharmaceutically acceptable carrier.

Claim 20. (Previously presented) The method of Claim 19, wherein said composition comprises 118 mg of said water-soluble fraction and 2 mg of said lipid-soluble fraction.